Bivastat 250 mg injection contains an active component called Bivalirudin. It is a medication used in cardiology and is primarily employed as an anticoagulant (blood thinner). It is often used in patients who are undergoing certain medical procedures, such as percutaneous coronary intervention (PCI) or angioplasty, to reduce the risk of blood clots forming during the procedure. It is often used as an alternative to heparin in patients at risk of or with a history of heparin-induced thrombocytopenia (HIT), a potentially serious complication of heparin therapy. Patients who have a known hypersensitivity or allergy to Bivalirudin or any of its components should not receive the medication. It is an anticoagulant and can increase the risk of bleeding. It is contraindicated in patients with active, severe, or life-threatening bleeding, such as gastrointestinal bleeding, intracranial bleeding, or bleeding disorders. It may not be suitable for patients with severely uncontrolled high blood pressure (hypertension). Patients with severe renal impairment or end-stage renal disease may require dosage adjustment or alternative anticoagulation strategies, as it can accumulate and increase the risk of bleeding. Patients with known coagulation disorders or conditions predisposing them to bleed may not be suitable for this medication. It is not recommended for patients with a significant decrease in platelet count (thrombocytopenia) or a history of heparin-induced thrombocytopenia (HIT) unless there are no suitable alternatives. It may not be appropriate for patients who have undergone recent major surgical procedures or experienced significant trauma due to the increased risk of bleeding. It is not recommended as the sole anticoagulant for patients with infective endocarditis or other conditions where a more extended duration of anticoagulation is needed. Bivastat 250 mg injection can be used in elderly patients, but with caution. It is not typically used in pediatric populations.